Genentech, Incorporated  
Attention: Todd W. Rich, M.D.  
Vice President, Clinical and Commercial Regulatory Affairs  
1 DNA Way, MS# 242  
South San Francisco, CA 94080  

Dear Dr. Rich: 

Your request to supplement your biologics license application for rituximab to revise the WARNING AND PRECAUTIONS; Progressive Multifocal Leukoencephalopathy (5.4) subsection to include information on progressive multifocal leukoencephalopathy occurring in rituximab-treated patients with rheumatoid arthritis has been approved.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission “Product Correspondence - Final SPL for approved STN BL103705/5291.” In addition, within 21 days of the date of this letter, amend any pending supplement(s) for this BLA with content of labeling in SPL format to include the changes approved in this supplement.

Marketing the product with labeling that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

We acknowledge your plan to issue a Dear Healthcare Provider Letter as described in your August 4, 2008 submission.

Please refer to http://www.fda.gov/cder/biologics/default.htm for information regarding therapeutic biological products, including the addresses for submissions.
This information will be included in your biologics license application file.

Sincerely,

[Signature]

Patricia Keegan, M.D.
Director
Division of Biologic Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure: Revised Labeling